VIA
OPRX icon

Vident Investment Advisory’s OptimizeRx OPRX Stock Holding History

Vident Investment Advisory’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,676
Closed -$228K – 1210
2021
Q2 		$228K Buy
+3,676
New +$187K 0.01% 1004

Other funds holding OPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Vident Investment Advisory's OPRX Position: Q3 2021 in Review

Vident Investment Advisory sold out of OptimizeRx (OPRX) in Q3 2021, closing a stake of 3,676 shares — an estimated $228K sold.

Vident Investment Advisory first reported a position in OPRX in Q2 2021 and held it in 1 quarter. The position peaked at $228K in Q2 2021. 163 funds tracked by Wall St. Rank hold OPRX as of Q3 2021.

  • Vident Investment Advisory reported no remaining OptimizeRx position as of Q3 2021 after selling out during the quarter.
  • Vident Investment Advisory sold 3,676 OptimizeRx shares in Q3 2021, an estimated $228K.
  • Vident Investment Advisory first reported a position in OptimizeRx in Q2 2021 and held it in 1 quarter.
  • Vident Investment Advisory's OptimizeRx position peaked at $228K in Q2 2021.
  • 163 funds tracked by Wall St. Rank held OptimizeRx as of Q3 2021.

Based on Vident Investment Advisory's 13F filing for Q3 2021, filed 12 Nov 2021.